4/25
02:00 am
vrna
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
Low
Report
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
4/16
10:10 am
vrna
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Low
Report
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
4/16
10:10 am
vrna
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Low
Report
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
4/16
08:00 am
vrna
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Piper Sandler from $31.00 to $36.00. They now have an "overweight" rating on the stock.
Low
Report
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Piper Sandler from $31.00 to $36.00. They now have an "overweight" rating on the stock.
3/4
08:06 am
vrna
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
3/4
02:06 am
vrna
Andrew Fisher Joins Verona Pharma as General Counsel [Yahoo! Finance]
Medium
Report
Andrew Fisher Joins Verona Pharma as General Counsel [Yahoo! Finance]
3/4
02:00 am
vrna
Andrew Fisher Joins Verona Pharma as General Counsel
Medium
Report
Andrew Fisher Joins Verona Pharma as General Counsel
3/1
09:18 am
vrna
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/1
09:03 am
vrna
Verona Pharma plc (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Medium
Report
Verona Pharma plc (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
2/29
06:45 am
vrna
Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/29
02:15 am
vrna
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/29
02:00 am
vrna
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Medium
Report
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2/15
06:25 pm
vrna
Verona Pharma: A Few Points From The Bull And Bear Case [Seeking Alpha]
Low
Report
Verona Pharma: A Few Points From The Bull And Bear Case [Seeking Alpha]
2/15
02:00 am
vrna
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
Medium
Report
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
2/1
02:16 am
vrna
Michael Austwick Joins Verona Pharma as Non-Executive Director [Yahoo! Finance]
Low
Report
Michael Austwick Joins Verona Pharma as Non-Executive Director [Yahoo! Finance]
2/1
02:00 am
vrna
Michael Austwick Joins Verona Pharma as Non-Executive Director
Low
Report
Michael Austwick Joins Verona Pharma as Non-Executive Director